Background. We describe an immune reconstitution syndrome (IRS)-like entity in the course of evolution of Cryptococcus neoformans infection in organ transplant recipients.
response, despite ongoing receipt of appropriate antifungal therapy and cultures that were negative for C. neoformans. Description of this phenomenon exists in the literature on HIV infection, in which immune restoration after effective antiretroviral therapy has been associated with an inflammatory response and exacerbation of clinical manifestations [4] [5] [6] [7] [8] [9] [10] [11] . This syndrome, known as "immune reconstitution syndrome" (IRS), is believed to result from enhanced-but partially reconstituted-pathogen-specific, cell-mediated immunity and induction of proinflammatory cytokines, leading to an exaggerated inflammatory reaction [5, 6, 11, 12] . We describe an IRS-like entity in transplant recipients with C. neoformans infection and propose its pathophysiologic basis.
METHODS
The patients were 83 organ transplant recipients with cryptococcosis who were identified at 22 transplantation centers in 5 countries. C. neoformans infection was defined as a positive result of a culture of a clinical specimen, histopathologic or cytopathologic examination of needle aspiration or biopsy specimens showing yeast cells, or a finding of cryptococcal antigen in blood or CSF specimens obtained from a patient with compatible clinical presentation [13] . Disseminated infection was defined as CNS infection or fungemia or у2 sites of involvement. The median duration of follow-up for the patients was 2 years (range, 30 days to 5 years).
Patients with an IRS-like entity were defined on the basis of criteria proposed for IRS in HIV-infected patients: (1) reappearance or worsening of previous manifestations after an initial response or appearance of new manifestations consistent with an infectious and/or inflammatory process, despite receipt of appropriate therapy; and (2) symptoms could not be explained by a newly acquired infection, by the expected clinical course of a previously recognized infectious agent, or by the adverse effects of therapy [14, 15] .
Statistical analysis was performed using Prophet Statistics, version 6.0 (AbTech). Fisher's exact test was used to compare categorical variables, and the Mann-Whitney U test was used to compare times to onset of infection.
RESULTS

Case Reports
Four organ transplant recipients had an IRS-like entity. Patient 1. Nine months after undergoing transplantation, a 57-year-old liver transplant recipient developed an ulcerative skin lesion and a 2-cm nodule in the right upper lobe of the lung that was proven to be due to C. neoformans on the basis of biopsies of both lesions. The patient's immunosuppressive regimen comprised tacrolimus, mycophenolate mofetil (MMF), and prednisone (5 mg q.d.). The serum cryptococcal antigen titer was 1:256. Findings of a CT of the head and CSF analyses were unremarkable. The regimen of tacrolimus, MMF, and prednisone was discontinued, and cyclosporine A therapy was started. Treatment with amphotericin B (0.7 mg/kg q.d.) and 5-flucytosine was initiated. Amphotericin B was switched to amphotericin B lipid complex (ABLC) 5 days later because of an elevated serum creatinine level. The serum cryptococcal antigen titer decreased to 1:64 at 4 weeks after initiation of antifungal therapy.
Five weeks after the initiation of antifungal therapy, the patient became confused and developed dyspnea. A left lower lobe infiltrate, which had not been previously present, and new enhancing nodules in the medial aspect of the left occipital lobe were documented. The serum cryptococcal antigen titer increased to 1:256. A transbronchial biopsy specimen and an inguinal mass (from the lymph node) revealed granulomas in which budding yeast cells of Cryptococcus were visualized histopathologically. However, culture did not yield C. neoformans. During the ensuing 8 weeks, new skin lesions continued to appear; however, none yielded cryptococci on culture. The patient received ABLC for a total of 10 weeks and was then prescribed fluconazole for 14 months. He remained well until 2 years after the initial infection, when he died of an acute myocardial infarction.
Patient 2. A 63-year-old male patient underwent renal transplantation for adult polycystic kidney disease. Three months after transplantation, myositis in the right forearm developed; culture of muscle biopsy and blood specimens yielded C. neoformans. The serum cryptococcal antigen titer was 1: 1024. The immunosuppressive therapy that he was receiving at the time comprised tacrolimus, MMF, and prednisone (20 mg q.d.). At the time of diagnosis, the dosage of MMF was gradually reduced and treatment with MMF was discontinued, the prednisone dosage was reduced to 15 mg every other day, and the tacrolimus dosage was reduced from 7 mg b.i. ABLC and 5-flucytosine were administered for 6 weeks and were then switched to fluconazole (200 mg po q.d.). He had been receiving fluconazole for only 2 days when he began experiencing fever, headache, nausea, and vomiting. CSF analysis now revealed 107 WBCs. However, all culture results were negative. LAMB therapy was initiated, and 5-flucytosine therapy was resumed. A protracted illness ensued, during which the allograft was lost; the patient died 5 months after his initial infection. Cryptococcal antigen titers ranged between 1:256 and 408. The serum cryptococcal antigen titer was 1:2048. LAMB and flucytosine were prescribed, and therapy was continued for 24 days. The serum creatinine level increased from a baseline level of 1.2-1.5 mg/dL to 2.5-3.1 mg/dL during this period. MMF therapy (500 mg q.i.d.) was discontinued briefly and then resumed at a dosage of 500 mg b.i.d. The prednisone dose was tapered, and the tacrolimus dose was modified such that, by day 7, the patient was receiving 2.5 mg of prednisone q.d. and 1 mg of tacrolimus b.i.d. CSF culture results were negative 13 days after initiation of antifungal therapy, and the CSF antigen titer decreased to 1:64.
Thirty-days after employment of the initial antifungal therapy regimen, while she was receiving fluconazole (400 mg q.d.), the patient presented with worsening neurological symptoms and obtundation. CSF analysis revealed 60 WBCs, the CSF antigen titer was 1:128, and the serum titer was 1:8000. India ink stains and cultures of CSF specimens yielded negative results. LAMB therapy was resumed and continued for 12 weeks. The patient was alive as of 3 years after infection.
Results
Overall, 4 (100%) of the 4 patients with an IRS-like entity were receiving tacrolimus, MMF, and prednisone as the immunosuppressive treatment regimen, compared with 21 (26.6%) of 79 other patients ( ). Case patients and all other pa-P p .007 tients did not differ significantly with regard to other variables assessed (table 1) .
DISCUSSION
Host defense against cryptococcal infections is critically regulated by cell-mediated immunity, of which T helper (Th) CD4 + cells are the major effector cells [16, 17] . A Th1 response (characterized by proinflammatory cytokines-for example, IFN-g) and TNF-a are protective against C. neoformans, whereas a Th2 response with the induction of IL-10 is associated with disease progression [16, [18] [19] [20] . Capsular polysaccharide of C. neoformans has been shown to stimulate IL-10 production and inhibit TNF-a and IL-1b secretion by human monocytes [21] . High IL-10 levels have been observed during cryptococcal infection [22] . Receipt of antifungal therapy was associated with a rebound in Th1 inflammatory response that led to exacerbation of clinical manifestations, but that facilitated the eradication of infection [23] . In HIV-infected patients with cryptococcosis, the levels of soluble TNF receptor II, an anti-inflammatory cytokine, decreased in response to antifungal therapy [24] . In 2 patients with idiopathic CD4 + lymphopenia, defective production of IFN-g and TNF-a-but not of IL-10-was documented [25] . One of these 2 patients with disease progression (despite receipt of antifungal treatment) was administered recombinant IFN-g, which resulted in restoration of immunological parameters and a sustained clinical recovery [25] .
IRS occurred in 8.3% of the HIV-infected patients with C. neoformans infection and correlated with more-profound immunosuppression (i.e., a lower CD4 + cell count at the onset of infection) [26] . An IRS-like entity was observed in 4.8% of the organ transplant recipients with cryptococcosis who we describe. Patients who received a combination of tacrolimus, MMF, and prednisone were more likely to develop this syndrome than were all other patients. Immunosuppressive agents, such as tacrolimus, suppress the production of cytokines stimulated by Th1 cells (e.g., IL-2 and INF-g), compared with those produced by Th2 cells [27] . Tacrolimus causes significantly greater suppression of production of IFN-g than cyclosporine A [27] . Corticosteroids, although less potent inhibitors, are also associated with a decrease in IL-2, IL-12, and IFN-g levels and an increase in IL-10 levels [28, 29] . After a reduction in or cessation of immunosuppressive therapy, a relative increase in Th1 response may have been greater in transplant patients receiving more-potent immunosuppression and could have accounted for the occurrence of IRS exclusively in these patients.
Of note is the development of lymphadenitis and granulomas in the lymph node and lung in patient 1. Such granulomas have been described in HIV-infected patients with IRS due to not only C. neoformans, but to other antigens as well [7, 30] . Granulomatous responses are strongly associated with containment and resolution of infection in humans as well as in laboratory animals [17, 31] . Although cryptococci may be visualized histopathologically, a consistent finding in IRS lesions in HIV-infected patients has been cultures that are negative for C. neoformans [7, 9, 10] . C. neoformans was not cultured in the 4 cases we describe. However, an increase in the cryptococcal antigen titer was observed, the basis for which is not known. Because tacrolimus has antifungal activity in vitro against C. neoformans, it is plausible that a reduction in the tacrolimus dose may have, in fact, led to the worsening of infection and an increase in the antigen titer [32, 33] .
In summary, we have described an IRS-like entity during the evolution of cryptococcal infection in organ transplant recipients. Features suggestive of an inflammatory or an immune response were observed (i.e., granuloma formation, CSF inflammation, and enhancing CNS lesions in the absence of cultures positive for C. neoformans). There was no other infection or alternative diagnosis to account for these manifestations. The proposed biological basis for this entity (figure 1) is based largely on animal studies and should be validated by data from studies of transplant recipients.
Our study has implications relevant for the management of cryptococcosis in transplant recipients. An exacerbation of symptoms and signs due to evolving host response in IRS may be misconstrued as failure of therapy or as a "relapse." The inflammatory reaction is deemed to be beneficial in the eradication of infection [34] . However, the induction of endogenous response may be suboptimal. This suggests a role for immunomodulatory therapies targeted toward augmenting cellular immunity, such as neutralization of suppressive cytokines, enhancement of Th1 responses with IFN-g, and transfer of adoptive cellular immunotherapy, as has been attempted for Aspergillus infection [34, 35] . An overzealous or heightened inflammatory response, on the other hand, may be life-threatening [5] and could potentially be worsened by the exogenous administration of proinflammatory cytokines, such as IFN-g. A potential concern with IFN-g also is the risk of exacerbation of allograft rejection. One might speculate whether the administration of IFN-g guided by the measurement of serum levels may be a logical approach for achieving the desired balance and optimal outcome.
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